Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGOBSERVATIONAL

Relationship Between Glycemic Control and Irisin in Type 2 Diabetic Patients With Sarcopenic or Non-sarcopenic Obesity

Relationship Between Parameters of Glycemic Control and Irisin Levels in Patients With Diabetes Mellitus Type 2 and Sarcopenic Obesity or Non-sarcopenic Obesity

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The goal of this observational study is to compare glycemic control and irisin levels in subjects with diabetes mellitus type 2 with sarcopenic obesity vs non-sarcopenic obesity. The main questions it aims to answer are: Is glycemic control worse in diabetic patients with sarcopenic obesity? Are irisin levels higher in patients with non-sarcopenic obesity? Participants will be asked to: * Fill in three questionaries on lifestyle * Perform two physical performance tests The investigators will collect the following data: * Anthropometric measurements * Body composition by bioelectrical impedance analysis. * Results of routine blood analyses * Irisin levels by drawing a vial of blood from the antecubital vein

Who May Be Eligible (Plain English)

Who May Qualify: - Diabetes mellitus type 2 diagnosed less than 10 years before - age \>60 years - BMI (Body Mass Index) \>30 kg/m2 - eGFR (estimated Glomerular Filtration Rate) \>30 ml/min - On stable antidiabetic therapy for at least 3 months Who Should NOT Join This Trial: - Insulin or insulin secretagogues use - Diabetes mellitus type 1, previous diabetic ketoacidosis - Neuromuscular diseases - Endocrinopathies that may cause myopathies (hypercortisolism, GH \[growth hormone\] deficiency, acromegaly, adrenal insufficiency, partial hypopituitarism or panhypopituitarism, male hypogonadism, hyperparathyroidism, hypoparathyroidism) - Severe vit. D deficiency (\<12 ng/ml) - Hemoglobinopathies - Prolonged immobilization - Pathologies with fluid retention (heart failure with NYHA \[New York Heart Association\] class III/IV, severe renal insufficiency, hepatic insufficiency) - Active tumors in the past 5 years - Severe arthritis of the knee or hip - Pacemaker wearer Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Diabetes mellitus type 2 diagnosed less than 10 years before * age \>60 years * BMI (Body Mass Index) \>30 kg/m2 * eGFR (estimated Glomerular Filtration Rate) \>30 ml/min * On stable antidiabetic therapy for at least 3 months Exclusion Criteria: * Insulin or insulin secretagogues use * Diabetes mellitus type 1, previous diabetic ketoacidosis * Neuromuscular diseases * Endocrinopathies that may cause myopathies (hypercortisolism, GH \[growth hormone\] deficiency, acromegaly, adrenal insufficiency, partial hypopituitarism or panhypopituitarism, male hypogonadism, hyperparathyroidism, hypoparathyroidism) * Severe vit. D deficiency (\<12 ng/ml) * Hemoglobinopathies * Prolonged immobilization * Pathologies with fluid retention (heart failure with NYHA \[New York Heart Association\] class III/IV, severe renal insufficiency, hepatic insufficiency) * Active tumors in the past 5 years * Severe arthritis of the knee or hip * Pacemaker wearer

Locations (1)

Policlinico di Bari
Bari, Italy